Deals In Depth: October 2012

In a deal valued at $272 million, AZ got exclusive global rights to Ardelyx’s NHE3 program. Pfizer exercised an option to buy spec pharma NextWave for $255 million up front. Biophama companies raised almost $2 billion in October propelled by public offerings. Early venture rounds dominated device financing, which totaled $193 million.

Exhibit 1

Top Alliances In October 2012

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deal-Making

More from In Vivo